ArticleBlood and lymphatic cancer : targets and therapy2025

An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma.

Luciano J Costa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.